Mast Therapeutics Inc (MSTX) Cut to “Neutral” at Laidlaw
Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by equities research analysts at Laidlaw to a “neutral” rating in a research report issued on Wednesday.
A number of other equities research analysts have also recently commented on the stock. Maxim Group cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research upgraded shares of Mast Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 30th. Roth Capital restated a “buy” rating and issued a $2.00 price target on shares of Mast Therapeutics in a report on Monday, August 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $3.00 price target on shares of Mast Therapeutics in a report on Thursday, July 28th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Mast Therapeutics has a consensus rating of “Hold” and an average target price of $3.33.
Shares of Mast Therapeutics (NASDAQ:MSTX) traded down 80.7458% during midday trading on Wednesday, hitting $0.1136. 107,632,799 shares of the stock were exchanged. The firm’s 50 day moving average is $0.46 and its 200-day moving average is $0.38. Mast Therapeutics has a 1-year low of $0.10 and a 1-year high of $0.71. The stock’s market capitalization is $24.06 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mast-therapeutics-inc-mstx-cut-to-neutral-at-laidlaw.html
Mast Therapeutics (NASDAQ:MSTX) last announced its earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts predict that Mast Therapeutics will post ($0.21) EPS for the current year.
A hedge fund recently raised its stake in Mast Therapeutics stock. Vanguard Group Inc. raised its position in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.
About Mast Therapeutics
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.